This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Blais, V. Articles by Rivest, S. Search for Related Content PubMed PubMed Citation Articles by Blais, V. Articles by Rivest, S.

In Altering the Release of Glucocorticoids, Ketorolac Exacerbates the Effects of Systemic Immune Stimuli on Expression of Proinflammatory Genes in the Brain

Laboratory of Molecular Endocrinology, Centre Hospitalier de l’Université Laval Research Center and Department of Anatomy and Physiology, Laval University, Québec, Canada G1V 4G2

Address all correspondence and requests for reprints to: Dr. Serge Rivest, Laboratory of Molecular Endocrinology, Centre Hospitalier de l’Université Laval Research Center and Department of Anatomy and Physiology, Laval University, 2705, Boulevard Laurier, Québec, Canada G1V 4G2. E-mail: serge.rivest{at}crchul.ulaval.ca.

Nonsteroidal antiinflammatory drugs (NSAIDs) are widely used for their antiinflammatory, antipyretic, and analgesic properties. The molecular basis for the therapeutic action of NSAIDs is believed to be in their ability to inhibit cyclooxygenase (COX) activity and thereby blocking the production of prostaglandins. Emerging evidence now suggests that NSAIDs can exert their pharmacological effects through other mechanisms. This study investigated the influence of a nonselective COX-inhibitor ketorolac on IL-1ß- and TNF-induced expression of proinflammatory genes in the brain. Systemic injection of both cytokines caused a rapid and transient transcriptional activation of COX-2 gene within the cerebral microvasculature, which was significantly enhanced by ketorolac. Expression of genes encoding the index of nuclear factor B activity and the chemokine monocyte chemoattractant protein-1 was also increased by the NSAID. We speculated here that such effect was indirectly mediated via an altered secretion of plasma glucocorticoids because ketorolac is a potent inhibitor of the hypothalamic-pituitary-adrenal axis during systemic inflammation. As expected, pretreatment with the glucocorticoid receptor antagonist RU-486 exacerbated the influence of systemic immune stimuli on proinflammatory signaling. In contrast, exogenous corticosterone abolished the effects of ketorolac on IL-1ß-induced COX-2 and monocyte chemoattractant protein-1 gene expression in the cerebral endothelium. This drug plays therefore a paradoxical role in its ability to inhibit the circulating levels of glucocorticoids that are essential inhibitory feedback on the proinflammatory signal transduction pathways and gene transcription. In altering the production of key prostaglandins that are involved in the control of hypothalamic-pituitary-adrenal axis, ketorolac may have proinflammatory properties in the central nervous system during systemic immune stimuli.

This article has been cited by other articles:

				L. Li, L. H. Thompson, L. Zhao, and J. L. Messina Tissue-Specific Difference in the Molecular Mechanisms for the Development of Acute Insulin Resistance after Injury Endocrinology, January 1, 2009; 150(1): 24 - 32. [Abstract] [Full Text] [PDF]

				S. Lee and C. Rivier Role Played by Hypothalamic Nuclear Factor-{kappa}B in Alcohol-Mediated Activation of the Rat Hypothalamic-Pituitary-Adrenal Axis Endocrinology, April 1, 2005; 146(4): 2006 - 2014. [Abstract] [Full Text] [PDF]

				I. Glezer and S. Rivest Glucocorticoids: Protectors of the Brain during Innate Immune Responses Neuroscientist, December 1, 2004; 10(6): 538 - 552. [Abstract] [PDF]